Neuropeptides
Volume 44, Issue 5 , Pages 421-429 , October 2010

Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats

  • Svetlana Semenova

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive, M/C 0603, La Jolla, CA 92093-0603, USA. Tel.: +1 (858) 534 1528; fax: +1 (858) 858 534 9917.
    • ,
  • Daniel Hoyer

      Affiliations

    • Psychiatry/Neuroscience Research, Novartis Institute for Biomedical Research, CH 4002 Basel, Switzerland
    • ,
  • Mark A. Geyer

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
    • ,
  • Athina Markou

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA

Received 11 December 2009 ,Accepted 29 April 2010.

References 

  1. Allen JP, Hathway GJ, Clarke NJ, Jowett MI, Topps S, Kendrick KM, et al. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur. J. Neurosci. 2003;17:1881–1895
  2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. American Psychiatric Press, Washington, DC.
  3. Balazs M, Schwarzberg H, Telegdy G. Effects of somatostatin on self-stimulation behaviour in rats pretreated with a receptor blocker. Eur. J. Pharmacol. 1988;149:141–144
  4. Baldo BA, Jain K, Veraldi L, Koob GF, Markou A. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol. Biochem. Behav. 1999;62:659–672
  5. Bassareo V, De Luca MA, Di Chiara G. Differential impact of pavlovian drug conditioned stimuli on in vivo dopamine transmission in the rat accumbens shell and core and in the prefrontal cortex. Psychopharmacology (Berl). 2007;191:689–703
  6. Bissette G. Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats. Pharmacol. Biochem. Behav. 2001;69:269–281
  7. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156:234–258
  8. Brownstein M, Arimura A, Sato H, Schally AV, Kizer JS. The regional distribution of somatostatin in the rat brain. Endocrinology. 1975;96:1456–1461
  9. Bruijnzeel AW, Markou A. Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats. Brain Res. 2005;1058:91–100
  10. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of “intact” animals. Brain Res. Brain Res. Rev. 2005;50:336–360
  11. Davis M, Falls WA, Campeau S, Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav. Brain Res. 1993;58:175–198
  12. De Bundel D, Aourz N, Kiagiadaki F, Clinckers R, Hoyer D, Kastellakis A, et al. Hippocampal sst1 receptors are autoreceptors and do not affect seizures in rats. Neuroreport. 2010;21:254–258
  13. Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson’s disease. J. Neural Transm. Gen. Sect. 1993;91:197–221
  14. Deutch AY, Cameron DS. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 1992;46:49–56
  15. Engin E, Stellbrink J, Treit D, Dickson CT. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience. 2008;157:666–676
  16. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C. Somatostatin, Alzheimer’s disease and cognition: an old story coming of age?. Prog. Neurobiol. 2009;89:153–161
  17. Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. J. Physiol. Paris. 2000;94:265–281
  18. Feifel D, Minor KL. Cysteamine blocks amphetamine-induced deficits in sensorimotor gating. Pharmacol. Biochem. Behav. 1997;58:689–693
  19. Fendt M, Koch M, Schnitzler HU. Somatostatin in the pontine reticular formation modulates fear potentiation of the acoustic startle response: an anatomical, electrophysiological, and behavioral study. J. Neurosci. 1996;16:3097–3103
  20. Geyer MA. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. Dialogues Clin. Neurosci. 2006;8:9–16
  21. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003;27:1071–1079
  22. Geyer MA, Russo PV, Masten VL. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol. Biochem. Behav. 1986;25:277–288
  23. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 1990;25:485–498
  24. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 2001;156:117–154
  25. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry. 2002;7:1039–1053
  26. Hathway GJ, Emson PC, Humphrey PP, Kendrick KM. Somatostatin potently stimulates in vivo striatal dopamine and γ-aminobutyric acid release by a glutamate-dependent action. J. Neurochem. 1998;70:1740–1749
  27. Hathway GJ, Humphrey PP, Kendrick KM. Evidence that somatostatin sst2 receptors mediate striatal dopamine release. Br. J. Pharmacol. 1999;128:1346–1352
  28. Holmes A, Wrenn CC, Harris AP, Thayer KE, Crawley JN. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 2002;1:55–69
  29. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull. 2009;35:549–562
  30. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 1995;16:86–88
  31. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, et al. SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist. Neurosci. Lett. 2004;361:132–135
  32. Ikeda H, Kotani A, Koshikawa N, Cools AR. Somatostatin receptors in the nucleus accumbens modulate dopamine-dependent but not acetylcholine-dependent turning behaviour of rats. Neuroscience. 2009;159:974–981
  33. Kenny PJ, Koob GF, Markou A. Conditioned facilitation of brain reward function after repeated cocaine administration. Behav. Neurosci. 2003;117:1103–1107
  34. Kluge C, Stoppel C, Szinyei C, Stork O, Pape HC. Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity. Learn Mem. 2008;15:252–260
  35. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–238
  36. Kornetsky C, Esposito RU, McLean S, Jacobson JO. Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch. Gen. Psychiatry. 1979;36:289–292
  37. Kungel M, Koch M, Friauf E. Cysteamine impairs the development of the acoustic startle response in rats: possible role of somatostatin. Neurosci. Lett. 1996;202:181–184
  38. Lee N, Radke JM, Vincent SR. Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists. Behav. Brain Res. 1988;29:179–183
  39. Lin D, Koob GF, Markou A. Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol. Biochem. Behav. 2000;65:407–417
  40. Mague SD, Andersen SL, Carlezon WA. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol. Psychiatry. 2005;57:120–125
  41. Mansbach RS, Geyer MA, Braff DL. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl). 1988;94:507–514
  42. Marazioti A, Kastellakis A, Antoniou K, Papasava D, Thermos K. Somatostatin receptors in the ventral pallidum/substantia innominata modulate rat locomotor activity. Psychopharmacology (Berl). 2005;181:319–326
  43. Marazioti A, Pitychoutis PM, Papadopoulou-Daifoti Z, Spyraki C, Thermos K. Activation of somatostatin receptors in the globus pallidus increases rat locomotor activity and dopamine release in the striatum. Psychopharmacology (Berl). 2008;201:413–422
  44. Markou A, Kenny PJ. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotox. Res. 2002;4:297–313
  45. Markou A, Koob GF. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology. 1991;4:17–26
  46. Markou A, Koob GF. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav. 1992;51:111–119
  47. Martin-Iverson MT, Radke JM, Vincent SR. The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum. Pharmacol. Biochem. Behav. 1986;24:1707–1714
  48. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J. Neurochem. 2004;89:1057–1091
  49. Pallis E, Thermos K, Spyraki C. Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur. J. Neurosci. 2001;14:763–767
  50. Pallis E, Vasilaki A, Fehlmann D, Kastellakis A, Hoyer D, Spyraki C, et al. Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology. 2009;34:952–963
  51. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198
  52. Paterson NE, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox. Res. 2007;11:1–32
  53. Pellegrino L, Pellegrino A, Cushman A. A Stereotaxic Atlas of the Rat Brain. second ed.. New York: Plenum Press; 1986;
  54. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA. 1995;92:12304–12308
  55. Rakovska A, Kiss JP, Raichev P, Lazarova M, Kalfin R, Milenov K. Somatostatin stimulates striatal acetylcholine release by glutamatergic receptors: an in vivo microdialysis study. Neurochem. Int. 2002;40:269–275
  56. Rakovska A, Javitt D, Raichev P, Ang R, Balla A, Aspromonte J, et al. Physiological release of striatal acetylcholine (in vivo): effect of somatostatin on dopaminergic-cholinergic interaction. Brain Res. Bull. 2003;61:529–536
  57. Ralph RJ, Caine SB. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J. Pharmacol. Exp. Ther. 2005;312:733–741
  58. Raynor K, Lucki I, Reisine T. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J. Pharmacol. Exp. Ther. 1993;265:67–73
  59. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol. Psychiatry. 1986;21:341–365
  60. Rubinow DR, Gold PW, Post RM, Ballenger JC. CSF somatostatin in affective illness and normal volunteers. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1985;9:393–400
  61. Sagar SM, Landry D, Millard WJ, Badger TM, Arnold MA, Martin JB. Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J. Neurosci. 1982;2:225–231
  62. Santis S, Kastellakis A, Kotzamani D, Pitarokoili K, Kokona D, Thermos K. Somatostatin increases rat locomotor activity by activating sst(2) and sst(4) receptors in the striatum and via glutamatergic involvement. Naunyn Schmiedebergs Arch. Pharmacol. 2009;379:181–189
  63. Semenova S, Markou A. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol. Psychiatry. 2003;54:1249–1264
  64. Siehler S, Nunn C, Hannon J, Feuerbach D, Hoyer D. Pharmacological profile of somatostatin and cortistatin receptors. Mol. Cell Endocrinol. 2008;286:26–34
  65. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999;22:521–527
  66. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998;24:285–301
  67. Tashev R, Belcheva S, Milenov K, Belcheva I. Behavioral effects of somatostatin microinjected into caudate putamen. Neuropeptides. 2001;35:271–275
  68. Thermos K, Radke J, Kastellakis A, Anagnostakis Y, Spyraki C. Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse. 1996;22:209–216
  69. Thermos K, Bagnoli P, Epelbaum J, Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina?. Pharmacol. Ther. 2006;110:455–464
  70. Vasilaki A, Papasava D, Hoyer D, Thermos K. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology. 2004;47:612–618
  71. Vecsei L, Klivenyi P. Somatostatin and Alzheimer’s disease. Arch. Gerontol. Geriatr. 1995;21:35–41
  72. Vecsei L, Widerlov E. Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview. Acta Psychiatr. Scand. 1988;78:657–667
  73. Vecsei L, Widerlov E. Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behaviour and open-field activity in rats. Neuropeptides. 1988;12:237–242
  74. Vecsei L, Widerlov E. Effects of somatostatin-28 and some of its fragments and analogs on open-field behavior, barrel rotation, and shuttle box learning in rats. Psychoneuroendocrinology. 1990;15:139–145
  75. Vecsei L, Schwarzberg H, Telegdy G. Comparative studies with linear and cyclic somatostatin on the self-stimulation of rats. Acta Physiol. Acad. Sci. Hung. 1982;60:165–168
  76. Vecsei L, Schwarzberg H, Telegdy G. The effect of somatostatin on self-stimulation behavior in atropine- and methysergide-pretreated rats. Eur. J. Pharmacol. 1983;91:89–93
  77. Vecsei L, Kiraly C, Bollok I, Nagy A, Varga J, Penke B, et al. Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacol. Biochem. Behav. 1984;21:833–837
  78. Vecsei L, Ekman R, Alling C, Widerlov E. Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat. J. Neural Transm. Gen. Sect. 1989;78:209–220
  79. Vincent SR, Johansson O. Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: a light and electron microscopic study. J. Comp. Neurol. 1983;217:264–270
  80. Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, L’Heritier A, et al. Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur. J. Neurosci. 2000;12:3761–3770
  81. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol. Cell Endocrinol. 2008;286:75–87
  82. Vlachou, S., Markou, A., 2010. Intracranial self-stimulation: the use of the intracranial self-stimulation procedure in the investigation of reward and motivational processes: effects of drugs of abuse. In: Olmstead, M.C. (Ed.), Animal Models of Drug Addiction. Human Press Inc., in press.
  83. Zeyda T, Diehl N, Paylor R, Brennan MB, Hochgeschwender U. Impairment in motor learning of somatostatin null mutant mice. Brain Res. 2001;906:107–114

PII: S0143-4179(10)00049-1

doi: 10.1016/j.npep.2010.04.008

Neuropeptides
Volume 44, Issue 5 , Pages 421-429 , October 2010

Article Tools

* Image Usage & Resolution